A phase III, randomized, double-blind, placebo-controlled, parallel-group, multi-center study to evaluate the efficacy and safety of M605108 in patients with acne vulgaris

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031200251

Enrollment

200

Registered

2020-12-16

Start date

2020-11-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne vulgaris

Interventions

Patients apply a sufficient quantity of benzoyl peroxide to cover the entire face (except the lips and around the eyes) once daily at night after they washed and dried their faces.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with acne vulgaris

Exclusion criteria

Exclusion criteria: -Patients with concurrent presense of serious cardiac, hepatic, renal, plumonary, hematologic, or other diseases considered inappropriate for paticipation in the clinical study -Patients with a history of hypersensitivity to investigational drug ingredients -Pregnant or lactating women

Design outcomes

Primary

Measure	Time frame
Percentage change in total lesion count from baseline to week 12	—

Secondary

Measure	Time frame
Percentage change in inflammatory lesion and non-inflammatory lesion counts from baseline to week 12	—

Contacts

Public ContactClinical Trials Infomation

Maruho Co.,Ltd. Kyoto R&D Center

ctinfo@mii.maruho.co.jp+81-75-325-3279

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026